Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study
oleh: Yael N Kusne, Heidi E Kosiorek, Matthew R Buras, Patricia M Verona, Kyle E Coppola, Kelley A Rone, Curtiss B Cook, Nina J Karlin
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2021-06-01 |
Deskripsi
Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survival compared (Kaplan–Meier and Cox proportional hazards). Mixed models compared hemoglobin A1c (HbA1c) and glucose during the year after cancer diagnosis. Results: Three-year overall survival was 72% (95% CI: 60–86%) for DM patients versus 80% (95% CI: 70–92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56–3.16; p = 0.51); mean DM HbA1c, 7.3%. Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.